Filtered by:
52 Programs
-
Microlearning Activity
Recent Developments in the Management of Relapsed/Refractory Multiple Myeloma from ASH 2025: BCMA-Targeted Therapy and Investigational Agents
-
-
S
-
S
-
-
S
-
S
-
-
Oncology Today with Dr Neil Love
Current and Future Role of CD19 x CD3 Bispecific T-Cell Engaging Antibodies in the Treatment of Acute Lymphoblastic Leukemia
-
-
B
-
B
-
-
B
-
B
-
-
Webinar Proceedings
Inside the Issue: The Emerging Role of Cereblon E3 Ligase Modulators in Multiple Myeloma
-
-
N
-
P
-
N
-
-
Webinar ProceedingsCases from the Community: Investigators Discuss Available Research Guiding the Management of Relapsed/Refractory Multiple Myeloma — What Happened at ASH 2025?
-
-
M
-
S
-
M
-